Ascorbic Acid
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Ascorbic Acid: Non-syndromic esophageal malformation
One-Sentence Summary
Ascorbic acid (vitamin C) is a water-soluble vitamin with antioxidant activity and a role as a cofactor in collagen synthesis. The TxGNN model predicts it may be relevant to non-syndromic esophageal malformation, with a score of 0.9996. No clinical trials and no publications currently support this prediction, so it is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 11 of 13; dormant: 2) |
| Number of DINs | 13 (marketed: 11) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this drug in the data compiled for this report. In general terms, ascorbic acid acts as an antioxidant and as a cofactor for the enzymes that stabilize collagen.
We could not identify a mechanistic link between these properties and non-syndromic esophageal malformation. This condition is a congenital structural defect of the esophagus, and it is not plausible that an antioxidant or collagen-cofactor vitamin would modify it. The very high score is a model-based prediction only. There are no trials or publications to support it, so the prediction should be treated as a hypothesis with no supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name |
|---|---|
| 00780634 | VITAMIN C |
| 02355981 | ASCOR L 500 |
| 02245214 | VITAMIN C |
| 02238890 | HOT LEMON RELIEF FOR SYMPTOMS OF COLD AND FLU EXTRA STRENGTH |
| 02359499 | MOVIPREP |
Thirteen licences are on record, of which 11 are valid. Only the first five are listed here.
Safety Considerations
Drug Interactions: 25 interactions were identified in total. Moderate-level interactions include:
- Amphetamine
- Aluminum hydroxide
- Benzphetamine
- Bortezomib
- Deferoxamine
- Dextroamphetamine
- Lisdexamfetamine
- Metamfetamine
Minor-level interactions include paclitaxel, pseudoephedrine, ethinylestradiol, cisplatin, doxorubicin, ephedrine, flecainide, fluphenazine, indinavir and mexiletine.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials or publications, and no plausible mechanism links ascorbic acid to a congenital structural malformation of the esophagus.
To proceed, the following is needed:
- Any preclinical or clinical study that directly addresses this condition
- A defined mechanistic hypothesis explaining how the drug could affect esophageal development
- Detailed mechanism of action data and the package insert warnings and contraindications from Health Canada
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.